Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15158304 | 0.80 | MEN1 (0.41) | ALDH1A1CYP2D6GSK3BMEN1KMT2A | |
| SCHEMBL926835 | 0.76 | GSK3B (0.44) | CYP2D6GSK3B | |
| SCHEMBL3403341 | 0.75 | GSK3B (0.40) | CYP2D6GSK3B | |
| SCHEMBL3403112 | 0.74 | GSK3B (0.46) | CYP2D6GSK3BMTOR | |
| SCHEMBL3402354 | 0.74 | RAB9A (0.36) | ALDH1A1CYP2D6GSK3BMEN1KMT2A | |
| SCHEMBL927707 | 0.73 | GSK3B (0.41) | CYP2D6GSK3BMTOR | |
| SCHEMBL928012 | 0.73 | GSK3B (0.41) | CYP2D6GSK3BMTOR | |
| SCHEMBL3401265 | 0.73 | KCNMA1 (0.44) | ALDH1A1MEN1KMT2AMTORMAPT | |
| SCHEMBL3397799 | 0.73 | GSK3B (0.44) | CYP2D6GSK3BMTOR | |
| SCHEMBL3398468 | 0.73 | MTOR (0.40) | ALDH1A1GSK3BLMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507470-B2 | Substituted arylamide oxazepinopyrimidone derivatives | SANOFI (FR) | 2013-08-13 | — | — | US | disclosed |
| EP-2247599-B1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI SA (FR) | 2012-11-28 | — | — | EP | disclosed |
| EP-2247598-B1 | SUBSTITUTED HETEROARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI SA (FR) | 2012-10-24 | — | — | EP | disclosed |
| US-20110015177-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-01-20 | — | — | US | disclosed |
| EP-2247599-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2010-11-10 | — | — | EP | disclosed |
| EP-2247598-A1 | SUBSTITUTED HETEROARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009095788-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095787-A1 | SUBSTITUTED HETEROARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
| EP-2085400-A1 | Substituted heteroarylamide oxazepinopyrimidone derivatives | Sanofi-Aventis (FR) | 2009-08-05 | — | — | EP | disclosed |
| EP-2085399-A1 | substituted arylamide oxazepinopyrimidone derivatives | Sanofi-Aventis (FR) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015177-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | WEE1, NHERF1, WEE2 | ALDH1A1 93/4885CYP2D6 55/4885GSK3B 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.